Literature DB >> 8095637

Idiopathic long QT syndrome: asking the right question.

B Singh1, S A al Shahwan, M A Habbab, S M al Deeb, N Biary.   

Abstract

Infants and young children cannot describe symptoms of cardiogenic syncope accurately. If the attention in such cases is focused on the seizure activity that may follow, the patient will be treated inappropriately with anticonvulsants. We report such a presentation in 4 infants and young children (ages 6 to 48 months) with idiopathic long QT syndrome. All patients presented with recurrent seizures. All patients had a corrected QT interval (QTc) > or = 0.44 s and none had deafness. The diagnosis was suspected by careful history-taking which revealed episodes of loss of consciousness before convulsions in all patients. All patients were treated successfully with propranolol and remained free of symptoms during the follow-up period of 1-2 years. Screening the other family members revealed a prolonged QTc in 9 out of 16, and a history of 3 sudden and unexplained deaths in two families.

Entities:  

Mesh:

Year:  1993        PMID: 8095637     DOI: 10.1016/0140-6736(93)90501-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  A 26-year-old woman with recurrent loss of consciousness.

Authors:  Mark R Benson; Vikas Kotagal; Hakan Oral
Journal:  J Gen Intern Med       Date:  2011-07-08       Impact factor: 5.128

2.  Clinical and genetic analysis of long QT syndrome in children from six families in Saudi Arabia: are they different?

Authors:  Zahurul A Bhuiyan; Safar Al-Shahrani; Ayman S Al-Khadra; Saleh Al-Ghamdi; Khalaf Al-Khalaf; Marcel M A M Mannens; Arthur A M Wilde; Tarek S Momenah
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

Review 3.  Congenital Long QT Syndrome: An Update and Present Perspective in Saudi Arabia.

Authors:  Zahurul A Bhuiyan; Safar Al-Shahrani; Jumana Al-Aama; Arthur A M Wilde; Tarek S Momenah
Journal:  Front Pediatr       Date:  2013-11-20       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.